Children, Pulmonary Vein Stenosis
Conditions
Brief summary
This pilot study evaluates the safety and feasibility of losartan in pediatric patients with pulmonary vein stenosis. It is an open label single arm interventional study. The patient population involves pediatric patients with stenosis in 2 or more pulmonary veins. Patients will be given losartan for 1 year. Outcomes include measures of safety/adverse events and progression of pulmonary vein stenosis.
Detailed description
This pilot study evaluates the safety and feasibility of losartan in pediatric patients with pulmonary vein stenosis. Large animal studies have demonstrated that losartan can ameliorate the progression of pulmonary vein stenosis in a surgical model of pulmonary vein stenosis. There is no safety data for losartan in children \< 6months of age or in children with pulmonary vein stenosis. Therefore, this study will test the safety and feasibility of losartan in children in an open label single arm interventional study. Patient inclusion criteria includes stenosis involving 2 or more pulmonary veins. Patients who are consented into the trial with be on losartan therapy for one year. They will undergo study visits every 3 months. Patients will be screened for adverse events through biochemical tests, routine clinical tests and questionnaires. An exploratory efficacy analysis will compare progression of pulmonary vein stenosis in children enrolled in losartan to a contemporary cohort of children with pulmonary vein stenosis, who did not receive losartan.
Interventions
DRUGLosartan
Losartan is given for 12 months
Sponsors
The Hospital for Sick Children
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Stenosis involving 2 or more pulmonary veins * Consent of parent/legal guardian or child(when appropriate)
Exclusion criteria
* History of angioedema or allergic reaction to angiotensin converting enzyme inhibitors * corrected gestational age of less than 40 weeks * severe renal dysfunction * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety:Number of participants with adverse events | 12 months | adverse events include hypotension, hyperkalemia, renal dysfunction |
| Feasibility:Number of participants eligible and recruited | 12 months | includes patient recruitment and compliance with protocol |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression of pulmonary vein stenosis: survival | 12 months | Progression of pulmonary vein stenosis measures include survival, morbidity and evidence of progression on clinical tests |
Countries
Canada
Outcome results
None listed